PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 29 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Continuous intake of specific maitake mushroom strains (Y10M) showed significant improvement in cognitive assessment in healthy Japanese individuals aged 60 or older [PMID:42055721]
Meta-analysis of preclinical evidence indicates that Grifola frondosa polysaccharides have significant antitumor effects [PMID:34271115]
Administration of G. frondosa in rats markedly decreased serum cholesterol, triacylglycerol, and low-density lipoprotein cholesterol levels [PMID:27536279, PMID:9255420]
G. frondosa polysaccharides reduced weight loss and hyperglycemia symptoms and regulated hepatic inflammation by modulating macrophage polarization in T2DM rats [PMID:39587947]
Maitake-fortified diets attenuated severe DSS-induced colitis in vitamin D-deficient mice [PMID:40509673]
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 37373268 (2023) — Anti-Cancer Potential of Edible/Medicinal Mushrooms in Breast Cancer. · International journal of molecular sciences
- 2.PMID: 40370689 (2024) — Neuroprotective Mushrooms. · NeuroImmune pharmacology and therapeutics
- 3.PMID: 36749053 (2023) — Maitake Medicinal Mushroom, Grifola frondosa (Agaricomycetes), and Its Neurotrophic Properties: A Mini-Review. · International journal of medicinal mushrooms
- 4.PMID: 33466429 (2021) — Bioactive Ingredients and Medicinal Values of Grifola frondosa (Maitake). · Foods (Basel, Switzerland)
- 5.PMID: 40509673 (2025) — Attenuative Effect of Grifola frondosa (Maitake Mushroom) on Severe DSS-Induced Colitis in Vitamin D-Deficient Mice.